How Weight Loss Drugs Are Reshaping What We Eat And Drink
JUN 8, 202620 MIN
How Weight Loss Drugs Are Reshaping What We Eat And Drink
JUN 8, 202620 MIN
Description
What happens when millions of people simply stop wanting that second beer? In this episode of Beer In Front, I take a deep dive into the rapidly growing world of GLP-1 medications such as Ozempic, Wegovy, Mounjaro, and Zepbound—and explore how these drugs are reshaping the food and beverage industry. While most coverage focuses on weight loss, the bigger story may be changing consumer behavior. Research suggests GLP-1 medications don't just reduce appetite, they may also reduce cravings for alcohol, snacks, and other highly rewarding foods by affecting the brain's dopamine reward system. <br /><ul><li>Why GLP-1 users are drinking significantly less alcohol</li><li>New research showing dramatic reductions in alcohol cravings</li><li>How wine, beer, and spirits are being affected differently</li><li>Why bars and restaurants are seeing smaller checks and fewer repeat drink orders</li><li>The projected $30-$55 billion impact on the food and beverage industry</li><li>How grocery shopping habits are changing</li><li>The opportunities for premium alcohol, craft beverages, and non-alcoholic alternatives</li><li>Why GLP-1 medications could become an important tool in treating alcohol use disorder</li><li>What breweries, bars, restaurants, and food companies need to do to adapt</li></ul>As adoption continues to grow and new oral versions of these medications reach the market, the effects on consumer spending and consumption habits may only accelerate.Whether you're in the beer business, restaurant industry, food manufacturing, or simply curious about how emerging health trends shape the economy, this episode explores one of the most important consumer shifts happening today.<br /><br /><b>Statistic</b> <b>Sources</b><br />1 in 8 U.S. adults currently on a GLP-1 drug <i>KFF Health Tracking Poll, Nov 2025</i><br />Up to 75% potential reduction in alcohol consumption <i>Morgan Stanley </i><br />25% of GLP-1 users stopped drinking entirely <i>Morgan Stanley</i><br />41% reduction in daily drinking (clinical trial) <i>JAMA Psychiatry</i><br /><i>2025</i> Wine down 52%, beer 43%, spirits 40% <i>EY-Parthenon Survey</i><br />10% of adults = 50% of all alcohol sold <i>U.S. alcohol consumption data</i><br />$30–55B projected F&B revenue loss by 2030–34 <i>J.P. Morgan</i><br /><i>Feb 2026</i> 23% of households contain a GLP-1 user <i>CNBC / industry data</i><br /><i>2026</i> Dinner traffic down 6% among regular users <i>Restaurant industry analysis, 2026</i><br /><br />Become a supporter of this podcast: <a href="https://www.spreaker.com/podcast/beer-in-front--5704447/support?utm_source=rss&utm_medium=rss&utm_campaign=rss">https://www.spreaker.com/podcast/beer-in-front--5704447/support</a>.<br /><br /><a href="https://beermediagroup.com/" target="_blank" rel="noreferrer noopener"><b>Beer Media Group</b></a>